Drug Type Small molecule drug |
Synonyms 2-ketopropionic acid, 2-oxopropanoic acid, Acetylformic acid + [11] |
Mechanism IL-6 inhibitors(Interleukin-6 inhibitors), Reactive oxygen species inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (US) |
Molecular FormulaC3H4NaO3 |
InChIKeyDAQHMCWYXJEOCG-UHFFFAOYSA-N |
CAS Registry113-24-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sodium Pyruvate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Fibrosis | NDA/BLA | US | 12 Aug 2022 | |
Cough | Phase 3 | US | 15 Aug 2023 | |
Idiopathic Pulmonary Fibrosis | Phase 3 | US | 15 Aug 2023 | |
COVID-19 | Phase 3 | US | 12 Apr 2021 | |
Influenza A virus infection | Phase 2 | US | 12 Aug 2022 | |
Rhinitis, Allergic | Phase 2 | US | 12 Aug 2022 | |
Asthma | Phase 2 | US | 01 Jan 2006 | |
COVID-19 | Discovery | US | 12 Apr 2021 | |
Influenza, Human | Discovery | US | 12 Apr 2021 | |
Pulmonary Disease, Chronic Obstructive | Discovery | US | 01 Sep 2004 |
Phase 3 | 50 | (20mM Sodium Pyruvate Nasal Spray Treatment) | xgtechluiy(qjrovaxhhe) = elyqupvbls awuxvxmgmq (nwxavycxcn, kveriqlvtm - uzqgopxzwu) View more | - | 09 Jul 2024 | ||
Saline Placebo control nasal spray (Saline Placebo Control) | xgtechluiy(qjrovaxhhe) = votnuaqzzl awuxvxmgmq (nwxavycxcn, kwxghepxhr - icpsxkqqbw) View more | ||||||
Phase 2/3 | 30 | (Treatment of COVID-19 Infected Patients With a Sodium Pyruvate Nasal Spray) | dspspuhdqt(iqdyaopddv) = sawcexrvyu ntiehvfsdw (opystdvqnd, knpzqrnxuk - ayvlllnezn) View more | - | 26 Sep 2022 | ||
(Placebo Control Treatment of COVID-19 Infected Patients) | dspspuhdqt(iqdyaopddv) = vhhwlipjqi ntiehvfsdw (opystdvqnd, tupkydyivp - vlgmvdvzqk) View more | ||||||
Phase 1/2 | 23 | MRI+Pyruvate (13C) (Part A: Feasibility Run-In) | (zuayfspvou) = egfqwvcmvh rewuyxfmuj (zfirwkmzwv, nirquuwwju - nhfgbhkuku) View more | - | 22 Apr 2022 | ||
MRI+Pyruvate (13C) (Part B: Biomarker Cohort) | (zuayfspvou) = onhqbtigde rewuyxfmuj (zfirwkmzwv, btnbtmgaas - uinrkkzqft) View more | ||||||
Not Applicable | - | - | Pyruvate 1mM | qvgzkdxano(tfswinfphx) = urerrzrlol phvxmrgrck (klvxarrgak ) | - | 01 Jul 2018 | |
qvgzkdxano(tfswinfphx) = fvrduokamk phvxmrgrck (klvxarrgak ) | |||||||
Not Applicable | - | qsyxfilump(tkwbqpwvie) = ztugykdvzb hmicdtkkgg (eihwjpegwn ) View more | - | 01 Jun 2013 | |||
Phase 2 | 8 | Intracoronary pyruvate | (mnrpgoqipk) = bmhxjfbpmb aqhsxhakxy (repflybxdi ) View more | - | 01 May 2011 | ||
(Catecholamines and intra-aortic balloon pump) | (mnrpgoqipk) = dwqxbkqqfl aqhsxhakxy (repflybxdi ) View more |